MP63: Bladder Cancer: Non-invasive III

Poster Session Moderator(s)

• 

  Christopher Anderson, MD (he/him/his)

  Columbia University Iriving Medical Center
• 

  Mark Gonzalgo, MD, PhD

  University of Miami Miller School of Medicine
• 

  Neema Navai, MD

  Professor, Urology
  MD Anderson Cancer Center

Presentations:

• 1:00 PM – 3:00 PM CST

  MP63-01: An Interim Analysis of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS)
  

  Poster Presenter: Girish S. Kulkarni, MD (he/him/his) – University of Toronto
• 1:00 PM – 3:00 PM CST

  MP63-02: Prospective Multi-institutional Validation of a 3-Gene mRNA Biomarker Panel for Detection and Surveillance of Non-Muscle Invasive Bladder Cancer
  

  Poster Presenter: Zachary Thomas Kornberg, MD (he/him/his)
• 1:00 PM – 3:00 PM CST

  MP63-03: Efficacy and safety of a novel 450 nm blue diode laser versus plasmakinetic electrocautery for the transurethral resection of non-muscle invasive bladder cancer: the protocol and result of a multicentre randomized controlled trial
  

  Poster Presenter: Kaijie Wu
• 1:00 PM – 3:00 PM CST

  MP63-04: One year oncological outcome updated analysis of a single-center prospective, randomized, controlled, non-inferiority trial: En bloc vs. conventional transurethral resection of bladder tumor
  

  Poster Presenter: Pietro Diana, MD – Fundació Puigvert
• 1:00 PM – 3:00 PM CST

  MP63-05: Outcomes in Patients (Pts) With Bacillus Calmette-Guerin (BCG)-Unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC) Who Underwent Radical Cystectomy (RC) Following Pembrolizumab (Pembro) Treatment in KEYNOTE-057 Cohort A
  

  Poster Presenter: Girish S. Kulkarni, MD (he/him/his) – University of Toronto
• 1:00 PM – 3:00 PM CST

  MP63-06: Bacillus Calmette-Guerin vs Immediate Radical Cystectomy in EAU Defined Very High-Risk Non-Muscle Invasive Bladder Cancer Patients
  

  Poster Presenter: ROBERTO CONTIERI, MD – Humanitas University
• 1:00 PM – 3:00 PM CST

  MP63-07: Sequential Endoluminal Doxorubicin and Gemcitabine Alternating with Sequential Mitomycin and Docetaxel for Multi-Failure Non-Muscle Invasive Urothelial Carcinoma of the Upper and Lower Urinary Tracts
  

  Poster Presenter: Ian Mitchell Mcelree, MS,BS
• 1:00 PM – 3:00 PM CST

  MP63-08: Clinical and genomic risk features of high grade T1 non-muscle invasive bladder cancer
  

  Poster Presenter: Carissa Chu, MD – Memorial Sloan Kettering Cancer Center
• 1:00 PM – 3:00 PM CST

  MP63-09: GENOMIC PROFILING OF UROTHELIAL CARCINOMA IN SITU OF BLADDER
  

  Poster Presenter: Seth Paul Lerner, MD – Baylor College of Medicine Scott Department of Urology
• 1:00 PM – 3:00 PM CST

  MP63-10: The Diagnostic Value of Urinary Cytology versus DNA Methylation Urine Biomarker Test for Surveillance of Non-muscle Invasive Bladder Cancer
  

  Poster Presenter: Seyedeh Sanam Ladi Seyedian, MD
• 1:00 PM – 3:00 PM CST

  MP63-11: Advanced Age (>70 Years) Does not Affect Oncological Outcomes in Non-Muscle Invasive Bladder Cancer Patients Treated with Adequate Bacillus Calmette-Guerin: A Competing Risk Analysis from a Tertiary Care Center.
  

  Poster Presenter: ROBERTO CONTIERI, MD – Humanitas University
• 1:00 PM – 3:00 PM CST

  MP63-12: The effects of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High-risk Non-Muscle Invasive Bladder Cancer: MITO-BCG (EUDRACT-2017-004540-37)
  

  Poster Presenter: Beatrice Turchi
• 1:00 PM – 3:00 PM CST

  MP63-13: Trials in Progress: A Phase I/II Trial of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette-Guérin (BCG) for Patients with BCG-Exposed High-Grade Non-Muscle Invasive Bladder Cancer (NMIBC)
  

  Poster Presenter: Christopher D. Gaffney, MD
• 1:00 PM – 3:00 PM CST

  MP63-14: Preliminary Results of First-in-Human Cryotherapy for Non Muscle Invasive Bladder Cancer
  

  Poster Presenter: Gilad E. Amiel, MD – RAMBAM Medical Center and Technion Medical School
• 1:00 PM – 3:00 PM CST

  MP63-15: T1 Sub-staging is Associated with Worse Oncological Outcomes For Patients Treated with Bacillus Calmette-Guerin or Immediate Radical Cystectomy.
  

  Poster Presenter: ROBERTO CONTIERI, MD – Humanitas University
• 1:00 PM – 3:00 PM CST

  MP63-16: Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection
  

  Poster Presenter: Qiang Lyu, MD
• 1:00 PM – 3:00 PM CST

  MP63-17: Photodynamic diagnosis (PDD) directed biopsies vs white light bladder mapping in patients with positive cytology and negative preoperative workup: an international multicenter retrospective study
  

  Poster Presenter: PAOLO GONTERO, MD (he/him/his) – Molinette Hospital
• 1:00 PM – 3:00 PM CST

  MP63-18: UriFind assay facilitates whole course management of urothelial carcinoma in a large multicentric, prospective China cohort
  

  Poster Presenter: XU CHEN (he/him/his) – Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univers
• 1:00 PM – 3:00 PM CST

  MP63-19: Adequate vs inadequate BCG intravesical therapy in intermediate and high risk NMIBC: total number of instillations is what really matters
  

  Poster Presenter: Mario de Angelis, MD (he/him/his) – San Raffaele Hospital